FDA Issues Nonnuke Warning

BY HIV Plus Editors

November 01 2009 12:00 AM ET

The Food and Drug Administration in August issued a warning regarding cases of a deadly skin infection and of liver failure linked with Intelence, a nonnucleoside reverse transcriptase inhibitor from Tibotec Therapeutics. Tibotec has received reports of one patient who died and another injured by toxic epidermal necrolysis linked with the drug, while a third HIVer experienced a hypersensitivity reaction and liver failure. HIVers prescribed Intelence are instructed to watch for early signs of skin rash and other hypersensitivity symptoms; doctors are urged to immediately stop treatment among patients developing a rash.

Tags: Features

Quantcast